This case-control study investigated whether previous infection with cytomegalovirus (CMV) was associated with coronary heart disease (CHD). In total, 312 patients of German nationality aged 40-68 years who had a coronary stenosis of 150% of the luminal diameter were recruited for study. Controls ( ) were voluntary blood donors. CMV serology was n ϭ 479 performed to determine presence of specific CMV antibodies (IgG, IgM, IgA ELA test; Medac, Hamburg, Germany). Rheologic and inflammatory markers were determined. The prevalence of specific IgG antibodies against CMV was 54.5% in cases and 49.9% in controls ( ). P ϭ .116 The odds ratio for CHD was 1.21 (95% confidence interval, 0.84-1.75) given a positive serostatus of specific IgG antibodies after adjustment for covariates. With the exception of Creactive protein in controls, none of the rheologic or inflammatory markers was associated with CMV serostatus. Thus, serologic evidence of previous infection with CMV was not a major risk factor for CHD in this population.
Cytomegalovirus (CMV) is a herpesvirus that causes one of the most common infections in adults, with a seroprevalence of ∼50% [1] . Once acquired, the infection persists lifelong and may undergo periodic reactivation, especially in immunosuppressed subjects [2] . Experimental data have shown that infection of chickens with an avian herpesvirus causes atherosclerotic lesions in coronary arteries [3] . Furthermore, it is possible to infect the human vascular wall with herpesviridae, which results in altered function related to atherosclerosis [4] .
Seroepidemiologic studies have suggested a 2-fold risk of coronary heart disease (CHD) among subjects with prior infection with CMV [5] . However, the evidence is not convincing, since the studies had a small sample size and control for known or suspected risk factors was insufficient. Furthermore, most of these studies were conducted in specific patient populations (e.g., after heart transplantation or after coronary interventions) and thus investigated the risk of secondary heart disease. To date, only two published studies have investigated the role of CMV infection in primary CHD, and these had controversial results [6, 7] .
We therefore conducted a case-control study to investigate the role of previous infection with CMV on the risk of cardiovascular disease, carefully controlling for other potentially confounding factors. We also considered inflammatory and rheologic parameters.
Methods
Study design and sampling. Study patients were of German nationality, were 40-68 years old, had undergone coronary angiography in the University of Ulm Medical Department between October 1996 and November 1997, and had coronary stenosis of 150% of the luminal diameter (inpatient response, 207 [95.8%] of 216). We also asked persons to participate if they had coronary angiography in the 6 months before October 1996 and had a stenosis of 150% (response rate, 105 [57.1%] of 184). Main exclusion criteria for cases included the following: first medical diagnosis of CHD 12 years previously, unstable angina pectoris, acute myocardial infarction within the past 4 weeks, febrile infection within the past 3 weeks, underlying malignant disease, and anticoagulant therapy within the past 2 weeks.
The control group was sampled over the same period of time from voluntary blood donors of German nationality who came to the local blood donor center at the University of Ulm. Controls were matched by age and sex. A sampling ratio of 1:1.5 was intended to ensure a high power of the study. Exclusion criteria for controls were history of self-reported physician-diagnosed CHD and acute infections or surgery within the prior 3 weeks (response among controls, 84.1%).
Data collection. A standardized questionnaire was used for all cases and controls by the same trained team of interviewers. Venous blood from cases was drawn between 8:00 a.m. and 2:30 p.m. (93% between 8:00 a.m. and noon) prior to coronary angiography and from controls within the same period after blood donation. Samples were aliquoted immediately and frozen at Ϫ70ЊC until analysis.
Laboratory methods.
All laboratory analyses were done in blinded fashion. We tested for anti-CMV antibodies with an established and licensed ELISA kit (CMV IgG, IgA, and IgM ELA Test; Medac, Hamburg, Germany) according to the manufacturer's directions. We also determined C-reactive protein (CRP) by 5-point standard curve calibrated with the World Health Organization's international reference standard for CRP immunoassay, 85/506 (produced by Immunological Medicine Unit, Royal Postgraduate ]) with presence of CHD n ϭ 5 was assessed after adjustment for age and sex using a x 2 statistic. We then used multivariable logistic regression to control for other known or suspected risk factors. Finally, inflammatory and rheologic parameters were compared between infected and uninfected persons among cases and controls using the Wilcoxon rank sum test.
Results
We enrolled 312 patients and 479 controls in the study. Of the cases, 267 (85.6%) were men. Mean age of cases and controls was 57.7 and 55.8 years, respectively. Cases had less education than controls (!10 years of education: 69.2% vs. 58.5%, respectively). There were also considerably more smokers among cases than controls (mean pack-years, 20.3 vs. 10.8), and cases had a higher mean body mass index (27.3 vs. 26.3 kg/m 2 ). Physician-diagnosed high blood pressure and/or hyperlipidemia, respectively, was reported for 57.7% and 67.3% of cases and 20.5% and 20.95% of controls. Histories of diabetes mellitus were reported by 13.5% of cases and 2.7% of controls. Table 1 shows the prevalence of a positive IgG, IgA, and IgM antibody titers against CMV in cases and controls. Whereas almost no positive IgA and IgM antibody titers were present, about half of the cases and controls had positive IgG antibodies against CMV. The prevalence of IgG antibodies was slightly higher in cases than in controls in both men and women, but the difference was not statistically significant ( after P ϭ .116 adjustment for age and sex).
Adjustment for other cardiovascular risk factors did not alter the results. The odds ratio (OR) for the presence of CHD given a positive specific CMV IgG antibody titer was 1.21 (95% confidence interval, 0.84-1.75) after adjustment for age, gender, body mass index, school education, smoking status, alcohol consumption, history of blood pressure, history of diabetes mellitus, and history of hyperlipidemia ( ). P ϭ .310 As shown in table 2, there was no clear difference regarding mean fibrinogen, plasma viscosity, and leukocyte count between the CMV IgG-positive and -negative cases and controls. However, CRP in general was lower in CMV IgG-negative subjects than in those who were CMV IgG-positive. This difference was statistically significant only among controls ( ). As ex-P ϭ .02 pected, controls, in general, had lower CRP values than the cases, regardless of CMV serostatus and, less clearly, lower fibrinogen and plasma viscosity values and leukocytes.
Discussion
In this case-control study, we investigated the role of a previous infection with CMV, as indicated by a positive IgG serotiter, in the development of primary CHD, but we found no relevant association between the two factors. Although a positive CMV IgG antibody titer may be associated with elevated CRP, it is not a major risk factor for the development of CHD.
These results are in concordance with those of Adler et al. [6] . In that study of 602 patients with angiographically defined stenosis of 150% in any coronary artery and of 279 patients without stenosis, CMV infection was not a major risk factor for development of CHD [6] . Unlike the study by Adler et al., we used healthy controls instead of hospital controls, because the latter have undergone a certain selection process and may not truly represent the reference population of the cases. In addition, we controlled for the major risk factors for CHD, including cigarette smoking, and according to our sample distribution we had a high power to detect even a modest association between CMV infection and CHD. In the only other published study dealing with risk of primary CHD and CMV infection, prevalence of CMV antibodies was 90% in the 157 cases and 74% in the controls [7] ; however, adjustment for other established risk factors to limit the potential of confounding was not done. In several studies, CMV infection was associated with atherosclerosis after heart transplantation [5, 8] and was a risk factor for restenosis following coronary atherectomy [9] . Both studies investigated the role of CMV infection in secondary atherosclerosis or after heart transplantation, and in both, endothelial damage or inflammation may reactivate latent CMV infection. It was suggested that the reactivated virus may cause excessive accumulation of smooth muscle cells through multiple mechanisms, including inhibition of p53 tumor suppressor gene, leading to development of restenosis [10] .
Laboratory and pathologic data support the idea that inflammation plays a role in progression of atherosclerosis [11] . A recent meta-analysis of prospective epidemiologic studies confirmed the association of fibrinogen, CRP, albumin, and leukocyte count with subsequent CHD, even though the underlying pathomechanism is not clear [12] .
Nieto et al. [13] reported that CMV antibody titers of serum (collected in 1974) were associated with hemostatic parameters, suggesting that CMV may have procoagulant properties. With the exception of CRP values, we found none of the other measured rheologic or inflammatory markers to be associated with CMV IgG serostatus. Yet, when looking at the results of our study, the following limitations should be considered.
We measured seroprevalence of IgG, IgA, and IgM titers only at one point in time and had no information on the exact time of infection. However, it is established that CMV infection in infancy and childhood is common [14] and that another peak of CMV incidence occurs in late adolescence and young adulthood, where transmission of CMV often occurs sexually. Another limitation may result from the use of blood donors as controls, which may be a selected group with respect to health risk. This may have led to some overestimation of the differences in seroprevalence between cases and controls. This potential problem was taken care of, however, by careful control of known and suspected risk factors for CHD and other socioeconomic factors in multivariate analysis, which did not materially change the results. Although the power of this study was insufficient to detect a very weak association between seroprevalence of CMV and CHD, it was 78% or 95% to detect an OR of 1.5 or 1.7 ( ), respectively. Despite these limitaa ϭ .05 tions, our data provide further evidence that previous infection with CMV plays no major role in development of CHD.
